| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2003 | US6509325 Method for inhibiting melanogenesis and uses thereof |
| 01/21/2003 | US6509322 Pharmaceutical compositions for topical use containing hyaluronic acid and its derivatives |
| 01/21/2003 | US6509320 Purine L-nucleosides, analogs and uses thereof |
| 01/21/2003 | US6509316 Administering therapeutically effective amount of inhibitor of phospholipase A2 to animal |
| 01/21/2003 | US6509313 Stimulation of immune response with low doses of cytokines |
| 01/21/2003 | US6509178 Process for preparing docosahexaenoic acid and docosapentaenoic acid with ulkenia |
| 01/21/2003 | US6509177 Cultivating on a medium comprising at least one organic nitrogen or carbon source, in submerged aerated conditions, a Pseudomonas bacterium strain capable of the biosynthesis of pseudomonic acid A |
| 01/21/2003 | US6509162 Methods for selectively modulating survivin apoptosis pathways |
| 01/21/2003 | US6509154 Product comprising at least a double stranded RNA combined with at least an antiviral agent |
| 01/21/2003 | US6509151 DNA molecule encoding a Mycobacterium protein and conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages |
| 01/21/2003 | US6509043 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| 01/21/2003 | US6509038 Antifungal compositions with improved bioavailability |
| 01/21/2003 | US6509037 A modified sustained release salt of diclofenac tablet comprising hydroxyethyl cellulose, silicon dioxide and anhydrous lactose as channeling agent, polyvinylpyrrolidone, talc and magnesium stearate in speacific weight ratio |
| 01/21/2003 | US6509035 Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same |
| 01/21/2003 | US6509029 Mixtures; food, cosmetics, drugs |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509027 Anticancer agent |
| 01/21/2003 | US6509016 Delaying recurrence of ganglioside 2 associated tumors; antibody comprising the light and heavy chain variable region sequences contained in seq id no: 2 and 4 |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509014 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema |
| 01/21/2003 | US6509013 Water insoluble crosslinked allyl amine homo- or copolymer and carrier; removing phosphate from gastrointestinal tract; hyperphosphatemia |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA2231195C Sustained release matrix for high-dose insoluble drugs |
| 01/21/2003 | CA2205442C Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants |
| 01/21/2003 | CA2204253C Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
| 01/21/2003 | CA2123704C Methods and compositions utilizing pure s(+)isomer fluoxetine |
| 01/21/2003 | CA2106952C A single dose vaccination system |
| 01/21/2003 | CA2098720C Cellular composition for the treatment of human or animal organisms |
| 01/21/2003 | CA2078106C Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| 01/21/2003 | CA2026690C Pleuromutilins |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/20/2003 | WO2002007655A1 Method for damaging thermo non-tolerance pathologic structures of a warm-blooded organism |
| 01/20/2003 | CA2416600A1 Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof |
| 01/20/2003 | CA2416577A1 Method for damaging thermo non-tolerance pathologic structures of a warm-blooded organism |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/17/2003 | WO2002009717A1 Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | WO2002006214A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/17/2003 | CA2416709A1 Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415954A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/16/2003 | WO2003005025A1 Methods for identifying compounds modulating the activity of ppar-gamma |
| 01/16/2003 | WO2003004734A1 Method for the production of low defect density silicon |
| 01/16/2003 | WO2003004668A1 Process for the production of allicin |
| 01/16/2003 | WO2003004667A1 Process for producing fat comprising triglyceride containing highly unsaturated fatty acid |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004509A2 C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| 01/16/2003 | WO2003004507A1 A kind of oligosaccharides, their sulfates and dendrimers, and the uses of these compounds |
| 01/16/2003 | WO2003004505A1 Oxaliplatin active substance with a very low content of oxalic acid |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004501A2 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004496A1 Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| 01/16/2003 | WO2003004495A1 Novel immunomodulating compounds |
| 01/16/2003 | WO2003004493A1 Novel compounds, their preparation and use |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004489A1 Compositions and methods for inhibiting prenyltransferases |
| 01/16/2003 | WO2003004488A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004485A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof |
| 01/16/2003 | WO2003004484A1 Novel aliphatic compounds, synthesis method and method of using the same |
| 01/16/2003 | WO2003004480A2 Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| 01/16/2003 | WO2003004479A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | WO2003004478A1 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) |
| 01/16/2003 | WO2003004475A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004472A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004470A1 Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 01/16/2003 | WO2003004468A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004458A1 New compounds |
| 01/16/2003 | WO2003004454A1 Linked cyclitols and their polysulfated derivatives |
| 01/16/2003 | WO2003004453A1 Compounds used to treat alcoholism |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004097A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 01/16/2003 | WO2003004096A2 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | WO2003004068A1 Hypertension treatment |
| 01/16/2003 | WO2003004064A2 Products for treating ovarian cancers and for preventing relapses |
| 01/16/2003 | WO2003004061A1 Uv-screening peptide-flavonoid conjugates |
| 01/16/2003 | WO2003004060A1 Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms |
| 01/16/2003 | WO2003004059A1 Treatment of parasitic disease |
| 01/16/2003 | WO2003004058A1 OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT |
| 01/16/2003 | WO2003004054A1 Ltb4 as vaccine aduvant |
| 01/16/2003 | WO2003004044A1 Fortified rice bran food product and method for promoting cardiovascular health |
| 01/16/2003 | WO2003004042A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 01/16/2003 | WO2003004039A2 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003004036A1 Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction |
| 01/16/2003 | WO2003004035A1 New use of a pyridazinone derivative |
| 01/16/2003 | WO2003004034A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 01/16/2003 | WO2003004033A1 Sustained release formulations of oxymorphone |
| 01/16/2003 | WO2003004032A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004031A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004030A1 Oxymorphone controlled release formulations |
| 01/16/2003 | WO2003004029A1 Methods of making sustained release formulations of oxymorphone related applications |
| 01/16/2003 | WO2003004028A1 Tetrahydroquinoline derivatives |
| 01/16/2003 | WO2003004027A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | WO2003004025A1 High purity amlodipine benzenesulfonate and a process for its preparation |
| 01/16/2003 | WO2003004024A1 Injectable sustained-release microspheres of huperzine a compounds |
| 01/16/2003 | WO2003004023A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |